Light Chain Amyloidosis Clinical Trials

4 recruiting

Light Chain Amyloidosis Trials at a Glance

8 actively recruiting trials for light chain amyloidosis are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Guangzhou, Nanjing, and Detroit. Lead sponsors running light chain amyloidosis studies include Beijing Boren Hospital, Institute of Hematology & Blood Diseases Hospital, China, and Alexion Pharmaceuticals, Inc..

Browse light chain amyloidosis trials by phase

Treatments under study

About Light Chain Amyloidosis Clinical Trials

Looking for clinical trials for Light Chain Amyloidosis? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Light Chain Amyloidosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Light Chain Amyloidosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1Phase 2

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Relapsed/Refractory Systemic Light Chain Amyloidosis
Regeneron Pharmaceuticals220 enrolled19 locationsNCT06292780
Recruiting
Phase 1Phase 2

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

AmyloidosisLight Chain AmyloidosisRelapsed AL Amyloidosis+1 more
Alexion Pharmaceuticals, Inc.91 enrolled18 locationsNCT07081646
Recruiting
Phase 2

BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis

Systemic Light Chain Amyloidosis
Institute of Hematology & Blood Diseases Hospital, China21 enrolled1 locationNCT07151690
Recruiting
Phase 1Phase 2

Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients

Systemic Light Chain Amyloidosis
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.70 enrolled23 locationsNCT07266116
Recruiting
Not Applicable

Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis

Light Chain Amyloidosis
Beijing Boren Hospital30 enrolled1 locationNCT06983951
Recruiting
Phase 2

Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis

Multiple Myeloma, Refractory to Standard TreatmentMultiple Myeloma, RelapsedLight Chain Amyloidosis
Polina Stepensky180 enrolled1 locationNCT06971380
Recruiting

The Impact of Systemic Light Chain Amyloidosis on Eyes

Systemic Light Chain AmyloidosisOcular Complications
Zhongshan Ophthalmic Center, Sun Yat-sen University130 enrolled1 locationNCT06803082
Recruiting
Phase 1

FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Light Chain Amyloidosis
Nanjing University School of Medicine12 enrolled1 locationNCT05978661